Drug
Csl300
Csl300: highest development phase Phase 2/3, developed by CSL. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| CSL300 NCT05485961 | Phase 2/3 | End Stage Kidney Disease |
| CSL300 NCT07619820 | Phase 1 | End Stage Kidney Disease (ESKD) |
Latest
No recent events.
Follow Csl300 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.